<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03877016</url>
  </required_header>
  <id_info>
    <org_study_id>PI2018_843_0028</org_study_id>
    <nct_id>NCT03877016</nct_id>
  </id_info>
  <brief_title>Pilot Study in Order to Evaluate Disconfort Among Outpatients Using actiTENS for Neuropathic Pain vs TENS ECO 2.</brief_title>
  <acronym>QolTENS</acronym>
  <official_title>Prospective, Multicentric, Randomized on Two Arms, Controlled, by Cross-over, Pilot Study, in Order to Evaluate Disconfort Among Outpatients Using actiTENS for Neuropathic Pain vs TENS ECO 2.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-pharmacological treatments for pain relief are more and more used in clinical care&#xD;
      although any scientific validation. Among the non-pharmacological treatments of neuropathic&#xD;
      pain relief, TENS (Electrical Nerve Stimulation Therapy) is the major treatment with the best&#xD;
      benefit. Unfortunately, the use of TENS by patients appears very difficult. Because of this&#xD;
      inconvenience, more than 40% of TENS users interrupt the treatment despite treatment benefit.&#xD;
      A new TENS device: actiTENS that seems to be less constraining than TENS is now available in&#xD;
      France. ActiTENS efficacy and safety compared to TENS need to be investigated.&#xD;
&#xD;
      The main objective is to evaluate and to compare the use of actiTENS, with TENS Eco 2, the&#xD;
      classical device in patients with chronic neuropathic pain.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 17, 2019</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disconfort of using TENS (Electrical Nerve Stimulation Therapy) Eco2 versus actiTENS</measure>
    <time_frame>day7 after patient inclusion</time_frame>
    <description>Discomfort evaluation will be determined by using VAS (Visual Analogue Scale)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disconfort of using TENS (Electrical Nerve Stimulation Therapy) Eco2 versus actiTENS</measure>
    <time_frame>day 35 after patient inclusion</time_frame>
    <description>Discomfort evaluation will be determined by using VAS (Visual Analogue Scale)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>length of TENS daily use</measure>
    <time_frame>day7 after patient inclusion</time_frame>
    <description>Length of TENS daily use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of TENS daily use</measure>
    <time_frame>day 35 after patient inclusion</time_frame>
    <description>Length of TENS daily use</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Neuropathic Pain</condition>
  <arm_group>
    <arm_group_label>TENS Eco2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TENS Eco2 is the classical device in patients with chronic neuropathic pain</description>
  </arm_group>
  <arm_group>
    <arm_group_label>actiTENS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ActiTENS is a new TENS device, that seems less cotraining.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TENS</intervention_name>
    <description>TENS Eco2 or actiTENS, both admitted and reimbursed in FRANCE according to regulation</description>
    <arm_group_label>TENS Eco2</arm_group_label>
    <arm_group_label>actiTENS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult&#xD;
&#xD;
          -  Patient covered by national health insurance&#xD;
&#xD;
          -  Patient able to express consent&#xD;
&#xD;
          -  Patient with neuropathic pain with DN4 (Douleur Neuropathique 4 Questions) &gt; or =&#xD;
             4/10.&#xD;
&#xD;
          -  Actual or potential neurologic lesion&#xD;
&#xD;
          -  Patient still using a TENS device&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Planned surgery in the next two months&#xD;
&#xD;
          -  Modification of the reatment in the next two motnhs&#xD;
&#xD;
          -  Other study ongoing for the patient&#xD;
&#xD;
          -  Medical contraindication for TENS&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric SERRA, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric SERRA, MD</last_name>
    <phone>(33)322668820</phone>
    <email>serra.eric@chu-amiens.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens Picardie</name>
      <address>
        <city>Amiens</city>
        <zip>80000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ERIC SERRA</last_name>
      <email>serra.eric@chu-amiens.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHD La Roche Sur Yon</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <zip>85000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yves Marie PLUCHON, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien NIZARD, MD,PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHP - Hopital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francoise LAROCHE, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie CANTAGREL, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>March 14, 2019</study_first_submitted>
  <study_first_submitted_qc>March 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2019</study_first_posted>
  <last_update_submitted>December 4, 2020</last_update_submitted>
  <last_update_submitted_qc>December 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neuropathic pain</keyword>
  <keyword>electrical nerve stimulation therapy</keyword>
  <keyword>patient report outcomes</keyword>
  <keyword>non-pharmalogical treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

